236 related articles for article (PubMed ID: 33895784)
41. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
42. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
Wells J; Jain N; Konopleva M
Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
[TBL] [Abstract][Full Text] [Related]
43. An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia.
Mohamed SMA; Schofield P; McCalmont H; Moles E; Friedrich KH; Kavallaris M; Christ D; Bayat N; Lock RB
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127596. PubMed ID: 37898250
[TBL] [Abstract][Full Text] [Related]
44. Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.
Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB
Cancer Res; 2016 Aug; 76(15):4579-91. PubMed ID: 27302164
[TBL] [Abstract][Full Text] [Related]
45. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
46. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
Xu N; Yang XF; Xue SL; Tan JW; Li MH; Ye J; Lou XY; Yu Z; Kang LQ; Yan ZQ; Yu L; Chen SN; Wang YT
Biochem Biophys Res Commun; 2022 Mar; 595():54-61. PubMed ID: 35101664
[TBL] [Abstract][Full Text] [Related]
47. Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.
Bayram N; Yaman Y; Özdilli K; Telhan L; Nepesov S; Bilgen H; Elli M; Behar SS; Anak S
Pediatr Transplant; 2021 Jun; 25(4):e14024. PubMed ID: 33860589
[TBL] [Abstract][Full Text] [Related]
48. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
[TBL] [Abstract][Full Text] [Related]
49. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
50. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
Huang TC; Cutler J; Bharne S; Zhong J; Weinstock D; Tyner J; Gojo I; Civin C; Pandey A
Leuk Lymphoma; 2015 May; 56(5):1524-7. PubMed ID: 25213184
[No Abstract] [Full Text] [Related]
51. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement.
Ge Z; Gu Y; Zhao G; Li J; Chen B; Han Q; Guo X; Liu J; Li H; Yu MD; Olson J; Steffens S; Payne KJ; Song C; Dovat S
Oncotarget; 2016 Aug; 7(31):49722-49732. PubMed ID: 27391346
[TBL] [Abstract][Full Text] [Related]
52. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.
Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DC; Lock RB
Blood; 2016 Sep; 128(10):1382-95. PubMed ID: 27343252
[TBL] [Abstract][Full Text] [Related]
53. Effects of different aberrations in the CRLF2 gene on the biological characteristics and drug sensitivities of Nalm6 cells.
Gu M; Jia Y; Xu M; Feng J; Tian Z; Ma X; Wang M; Wang J; Xu Y; Rao Q; Hao L; Mi Y; Yang W
Int J Lab Hematol; 2021 Jun; 43(3):441-449. PubMed ID: 33615710
[TBL] [Abstract][Full Text] [Related]
54. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.
Hurtz C; Wertheim GB; Loftus JP; Blumenthal D; Lehman A; Li Y; Bagashev A; Manning B; Cummins KD; Burkhardt JK; Perl AE; Carroll M; Tasian SK
J Clin Invest; 2020 Jul; 130(7):3637-3653. PubMed ID: 32191635
[TBL] [Abstract][Full Text] [Related]
55. Genomic and proteomic characterization of Philadelphia-like B-lineage acute lymphoblastic leukemia: A report of Indian patients.
Gupta DG; Varma N; Kumar A; Naseem S; Sachdeva MUS; Sreedharanunni S; Binota J; Bose P; Khadwal A; Malhotra P; Varma S
Cancer; 2023 Apr; 129(8):1217-1226. PubMed ID: 36738086
[TBL] [Abstract][Full Text] [Related]
56. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
57. Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
Potter N; Jones L; Blair H; Strehl S; Harrison CJ; Greaves M; Kearney L; Russell LJ
Leukemia; 2019 Apr; 33(4):893-904. PubMed ID: 30487598
[TBL] [Abstract][Full Text] [Related]
58. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.
Palmi C; Savino AM; Silvestri D; Bronzini I; Cario G; Paganin M; Buldini B; Galbiati M; Muckenthaler MU; Bugarin C; Della Mina P; Nagel S; Barisone E; Casale F; Locatelli F; Lo Nigro L; Micalizzi C; Parasole R; Pession A; Putti MC; Santoro N; Testi AM; Ziino O; Kulozik AE; Zimmermann M; Schrappe M; Villa A; Gaipa G; Basso G; Biondi A; Valsecchi MG; Stanulla M; Conter V; Te Kronnie G; Cazzaniga G
Oncotarget; 2016 Sep; 7(37):59260-59272. PubMed ID: 27449287
[TBL] [Abstract][Full Text] [Related]
59. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
60. [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].
Zheng YZ; LE SH; Zheng H; Hua XL; Chen ZS; Zheng L; Chen C; Li M; Cai CX; Yang JH; Chen YQ; Gao QL; Chen YY; Li J; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):311-315. PubMed ID: 33812392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
